Skip to main content
Log in

ACUTE LYMPHOBLASTIC LEUKEMIA

Quantifying measurable residual disease correctly

  • Correspondence
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Feng Y, Qi S, Liu X, Zhang L, Hu Y, Shen Q, et al. Have we been qualifying measurable residual disease correctly? Leukemia. 2023. https://doi.org/10.1038/s41375-023-02026-4.

  2. Latham S, Hughes E, Budgen B, Mechinaud F, Crock C, Ekert H, et al. Sources of error in measurement of minimal residual disease in childhood acute lymphoblastic leukemia. PLoS One. 2017;12:e0185556.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

This letter does not contain original research, has not been published elsewhere, has not been submitted for publication elsewhere and is exclusively the contribution of the author.

Corresponding author

Correspondence to Alexander A. Morley.

Ethics declarations

Competing interests

The author declares no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morley, A.A. Quantifying measurable residual disease correctly. Leukemia 38, 221–222 (2024). https://doi.org/10.1038/s41375-023-02106-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-023-02106-5

  • Springer Nature Limited

Navigation